Recent advances in diagnosis and therapy in systemic mastocytosis
Hyun Jung Lee
Abstract
mutation were introduced as minor diagnostic criteria after the introduction of highly sensitive screening methods. SM has a wide spectrum of clinical features, and only a few drugs are effective at treating advanced SM. Currently, the mainstay of SM treatment is limited to the management of chronic symptoms related to release of mast cell mediators. Small-molecule kinase inhibitors targeting the KIT-downstream and KIT-independent pathways were recently approved for treating advanced SM. I describe recent advances in diagnosis of SM, and review the currently available and emerging therapeutic options for SM management.
Topics & Concepts
Systemic mastocytosisMedicineTargeted therapyCutaneous MastocytosisProto-Oncogene Proteins c-kitMast cellSystemic therapyBioinformaticsPathologyInternal medicineImmunologyCancerHaematopoiesisStem cellStem cell factorGeneticsBiologyBreast cancerMast cells and histamineAutoimmune Bullous Skin DiseasesUrticaria and Related Conditions